Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study

Data from a prospective, real-world, observational cohort study demonstrated treatment outcomes among patients with HER2+ metastatic breast cancer receiving pyrotinib equivalent to that of patients enrolled in pyrotinib phase II and III clinical trials. After a median follow-up of 17.2 months, real-world data showed a median progression-free survival (PFS) of 14.1; median PFS and overall survival were 15.2 and 19.8 months, respectively, among patients with brain metastases.